



CIN No. L24232PB1983PLC005426

GST No. 03AAACK6458M1ZB

D.L. No. 1800-OSP, 1804-B

I.E. Code No. 1293001210

KWALITY PHARMACEUTICALS LIMITED

Regd. Office: Village Nag Kalan, Majitha Road, Amritsar - 143 601 (INDIA)

Phone : 91-8558820862 (Accounts)
: 91-8558820863 (Admin.)
: 91-9915743720 (Exports)
M.D. Mobile : 91-9814071215, 9814052314
E-mail : export@kwalitypharma.com
ramesh@kwalitypharma.com

To
The BSE Limited
Department of Corporate Services,
P.J. Towers, Dalal Street,
Mumbai-400001

Date: January 02, 2025

Scrip Code: 539997

Subject : Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 – Kwality Pharmaceutical Ltd receives RCGM Approval to Advance for Pre-Clinical Studies of Erythropoietin (10,000 IU/mL)

Dear Sir/Madam,

Kwality Pharmaceuticals Limited (KPL) is pleased to announce that it has secured approval from the **Review Committee on Genetic Manipulation (RCGM)** to commence pre-clinical toxicity studies for our recombinant Erythropoietin product, **10,000 IU/mL**, developed in its Biologics Unit.

Erythropoietin is a critical therapeutic used to treat anemia associated with **chronic kidney disease (CKD)**. This milestone marks a significant step forward in our commitment to expanding our biologics portfolio and addressing critical healthcare needs.

With this approval, Kwality Pharmaceuticals is on track to complete the pre-clinical studies and is diligently preparing for the **commercialization of the product in the next fiscal**.

The above is for your information and dissemination to the stakeholders.

For **Kwality Pharmaceuticals Limited**

Ramesh Arora
Managing Director
DIN: 00462656

